AnticoagEvaluator vs IVUSAID
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
AnticoagEvaluator
This medical app assists healthcare professionals in making informed decisions regarding antithrombotic therapy for patients with non-valvular atrial fibrillation. It calculates patient risk factors, provides guideline-driven therapy recommendations, and helps optimize anticoagulant dosages.
- Calculate renal function and stroke/bleed risk
- Review ACC/AHA/HRS guideline therapy
- Generate individualized antithrombotic risk
- Optimize DOAC dosages
- Based on SPARC Tool
Read full descriptionHide full description
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator. Use the app to: • Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed • Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention • Generate individualized risk for antithrombotic therapy options based on individual clinical trials. • Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics. This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
IVUSAID
This free educational app teaches medical professionals how to use intravascular ultrasound (IVUS) for PCI guidance. It features interactive lessons, image interpretation tools, and complex case studies to overcome barriers to IVUS adoption.
- IVUS principles and image acquisition
- Image interpretation with videos and descriptions
- Complex coronary case studies
- Interactive quiz section with explanations
- PCI guidance for stent sizing and optimization
Read full descriptionHide full description
The IVUSAID App is a free educational mobile application which has been developed to teach medical professionals how to use intravascular ultrasound (IVUS) for PCI guidance based on the current guidelines using our extensive experience and large database of complex coronary cases. Despite the growing body of evidence for clinical benefits of IVUS-guided PCI, IVUS remains underutilized in much of the world including the United States. Challenges in image interpretation and education are among the barriers to widespread adoption of IVUS in everyday clinical practice. Mount Sinai Heart is a global leader within the field of interventional cardiology as well as mobile apps development. The myriad of cases and pathology which are seen in The Mount Sinai Cardiac Catheterization Laboratory make it the perfect center to educate medical professionals within this field. The Key Concepts section of IVUSAID describes principles of IVUS, image acquisition, and concepts of ultrasound behavior in various tissues. The Image Interpretation section of the app has dozens of representative cross-sectional images, videos, and descriptions of plaque types, stent apposition and expansion, artifacts, and more. A short video for each type of lesion or artifact and post-stent findings, in addition to an annotated representative cross section aims to overcome a major limitation of any article or book on IVUS which present a static image, since the actual IVUS pullback is dynamic. Twenty-one complex coronary cases demonstrate IVUS guidance in a variety of patient presentations and lesions including ACS, LM bifurcation, severely calcified lesions and calcified nodules, spontaneous coronary artery dissection, and malapposed stents as well as how IVUS was used to inform treatment decisions. An extensive quiz section helps deliver educational content in a more interactive format where answers are accompanied by detailed explanations and references. We hope that IVUSAID will help techs, fellows, and early-career physicians incorporate IVUS in their daily practice for stent sizing, post-stent optimization, and identification of appropriate treatment strategies.
Screenshots
Verdict
The clearest difference is rating: IVUSAID at 5.0 against AnticoagEvaluator's 2.3. AnticoagEvaluator's advantage is ads (none vs listed) and update cadence (every 7 months vs every 18 months). On price, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ad data · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
IVUSAID holds the better App Store score, 5.0 against 2.3. Both are backed by a comparable volume of ratings — 3 and 1 respectively.
AnticoagEvaluator ships an update every 7 months, IVUSAID every 18 months. The most recent releases landed on November 20, 2026 and November 14, 2026 respectively.
| Parameter | AnticoagEvaluator | IVUSAID |
|---|---|---|
| Price | Free | Free |
| Rating | 2.3 (3 ratings) | 5.0 (1 ratings) — better |
| Positive reviews | 30.0% of reviews | — |
| Number of ratings | 3 — better | 1 |
| Update frequency | Every 7 months — better | Every 18 months |
| Ad data | No — better | Yes |
| In-app purchases | No | No |
| Monetization | Free — better | Ad-supported |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 11.0 — better | 15.0 |
| Further details — not scored | ||
| Size | 25 MB | 80 MB |
| Age rating | 17+ | 17+ |
| Developer | American College of Cardiology | Cardiology Apps LLC |
Customer experience
AnticoagEvaluator
IVUSAID
In-app purchases
AnticoagEvaluator
No in-app purchases
IVUSAID
No in-app purchases
Questions
Is AnticoagEvaluator free?
Is IVUSAID free?
Which has better reviews, AnticoagEvaluator or IVUSAID?
Do AnticoagEvaluator or IVUSAID have ads?
Which is updated more often, AnticoagEvaluator or IVUSAID?
Other comparisons















